MAYO CLINIC

BridgeBio Pharma's Attruby (acoramidis) approved by FDA for ATTR-CM, significantly reducing cardiovascular death and hospitalization in Phase 3 study. Attruby stabilizes TTR, mimicking a natural rescue mutation, and improves quality of life for patients with amyloidosis.

BridgeBio secures FDA approval for acoramidis (Attruby) for ATTR-CM, showing 42% reduction in mortality/cardiovascular events and 50% reduction in cumulative events at 30 months. The drug stabilizes transthyretin protein, reducing amyloid fibril build-up and disease progression.

BriaCell Therapeutics to present positive survival data for Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer at SABCS® 2024, showing a median overall survival of 13.4 months, a 9.5% objective response rate, and a 55% clinical benefit rate across all breast cancer subtypes.

The FDA approved Attruby, an oral treatment reducing heart-related deaths and hospital visits in adults with transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby stabilizes weak TTR protein, slowing disease progression and improving heart health faster than standard treatments. A clinical trial showed Attruby reduced deaths and hospital visits by 42% and heart failure risk by 50%. Mild side effects were noted, but resolved easily. BridgeBio offers a patient support program for Attruby users.

The FDA approved acoramidis (Attruby) for ATTR-CM, reducing cardiovascular death and hospitalization. It's the first near-complete TTR stabilizer, showing a 42% reduction in mortality and 50% in hospitalization events.

Acoramidis received FDA approval for treating transthyretin amyloid cardiomyopathy (ATTR-CM), based on significant results from the ATTRibute-CM study. The drug aims to reduce cardiovascular death and hospitalizations, showing a win ratio of 1.8 over placebo. Acoramidis stabilizes TTR proteins, improving outcomes and offering a new treatment option for ATTR-CM patients.

FDA approves BridgeBio’s Attruby (acoramidis) for ATTR-CM, the first treatment to near-completely stabilize Transthyretin (TTR). Attruby demonstrated rapid benefits in Phase III studies, reducing mortality and hospitalizations, and improving quality of life. The approval is based on the ATTRibute-CM study, with a European Medicines Agency decision expected in 2025.

Acoramidis (Attruby) received FDA approval for treating wild-type or variant transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization. It offers near-complete TTR stabilization in an oral tablet, competing with Tafamidis. The approval was based on the ATTRibute-CM trial, showing favorable safety and efficacy profiles, though some endpoints lacked significant reduction. Acoramidis is priced at just under $19,000 for a 28-day supply and is also under review in Europe, Japan, and Brazil.

BridgeBio Pharma's Attruby™ (acoramidis) receives FDA approval for treating ATTR-CM, reducing cardiovascular death and hospitalization. The ATTRibute-CM Phase 3 study showed significant benefits, with Attruby stabilizing Transthyretin (TTR) and improving patient outcomes. BridgeBio shares surged 25% post-approval. The company plans global expansion, with Europe, Japan, and Brazil as next targets. Scotiabank analyst Greg Harrison raised BridgeBio's price target to $48.00.

Tanios S. Bekaii-Saab, MD, discusses advancements in pancreatic cancer treatment, emphasizing genomic analysis for personalized medicine, especially for patients with RAS mutations and other targetable genomic alterations. He highlights the potential of targeted agents in earlier treatment settings and expresses optimism about improving patient outcomes.